ACRS - CIK 0001557746
Aclaris Therapeutics, Inc. (ACRS) reported net income of -$64.92M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$64.92M | +50.8% |
| FY 2024 | -$132.06M | -49.3% |
| FY 2023 | -$88.48M | -1.8% |
| FY 2022 | -$86.91M | +4.4% |
| FY 2021 | -$90.86M | -78.1% |
| FY 2020 | -$51.02M | +68.4% |
| FY 2019 | -$161.35M | -21.6% |
| FY 2018 | -$132.74M | -93.7% |
| FY 2017 |
Aclaris Therapeutics, Inc. (ACRS) reported net income of -$64.92M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Aclaris Therapeutics, Inc.'s net income declined from -$5.24M to -$64.92M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$68.52M |
| -42.5% |
| FY 2016 | -$48.08M | -133.8% |
| FY 2015 | -$20.56M | -141.4% |
| FY 2014 | -$8.52M | -62.7% |
| FY 2013 | -$5.24M | - |